^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
GENE:

LAMTOR4 (Late Endosomal/Lysosomal Adaptor)

i
Other names: LAMTOR4, Late Endosomal/Lysosomal Adaptor, MAPK And MTOR Activator 4, C7orf59, Late Endosomal/Lysosomal Adaptor And MAPK And MTOR Activator 4, Ragulator Complex Protein LAMTOR4, Chromosome 7 Open Reading Frame 59, UPF0539 Protein C7orf59
Associations
Trials
over1year
Elevated LAMTOR4 Expression Is Associated with Lethal Prostate Cancer and Its Knockdown Decreases Cell Proliferation, Invasion, and Migration In Vitro. (PubMed, Int J Mol Sci)
Our data further showed that knockdown of LAMTOR4 in the LNCaP cell line significantly dysregulated the β catenin/mTOR pathway and tumorigenesis associated pathways. Inhibiting components of the mTOR pathway, including LAMTOR4, might offer a strategy to inhibit tumor progression and metastasis in prostate cancer.
Preclinical • Journal
|
PTEN (Phosphatase and tensin homolog) • LAMTOR4 (Late Endosomal/Lysosomal Adaptor)
almost2years
The Absence of Intra-Tumoral Tertiary Lymphoid Structures is Associated with a Worse Prognosis and mTOR Signaling Activation in Hepatocellular Carcinoma with Liver Transplantation: A Multicenter Retrospective Study. (PubMed, Adv Sci (Weinh))
The classifier demonstrates remarkable performance in predicting intra-tumoral TLS abundance in both training and test sets, achieving areas under receiver operating characteristic curve (AUCs) of 92.9% and 90.2% respectively. In summary, the absence of intra-tumoral TLS abundance is associated with mTOR signaling activation and uncontrolled cell cycle progression in tumor cells, indicating unfavorable prognosis in HCC-LT.
Retrospective data • Journal
|
PSMC2 (Proteasome 26S Subunit, ATPase 2) • LAMTOR4 (Late Endosomal/Lysosomal Adaptor) • RHEB (Ras Homolog, MTORC1 Binding)
over2years
Integrative analysis of circadian clock with prognostic and immunological biomarker identification in ovarian cancer. (PubMed, Front Mol Biosci)
Collectively, 15 crucial CC genes showing indicative values for prognosis and immune microenvironment of OC were comprehensively identified. These findings provided insight into the further exploration of the molecular mechanisms of OC.
Journal • PD(L)-1 Biomarker • IO biomarker
|
PD-L1 (Programmed death ligand 1) • CD8 (cluster of differentiation 8) • CTLA4 (Cytotoxic T-Lymphocyte Associated Protein 4) • CHD1 (Chromodomain Helicase DNA Binding Protein 1) • LAMTOR5 (Late Endosomal/Lysosomal Adaptor) • ARNTL (Aryl Hydrocarbon Receptor Nuclear Translocator Like) • IL1B (Interleukin 1, beta) • NLRP3 (NLR Family Pyrin Domain Containing 3) • IL16 (Interleukin 16) • IL33 (Interleukin 33) • LAMTOR4 (Late Endosomal/Lysosomal Adaptor)
|
PD-L1 expression • CTLA4 expression
almost3years
B-Cell Receptor Signaling Is Thought to Be a Bridge between Primary Sjogren Syndrome and Diffuse Large B-Cell Lymphoma. (PubMed, Int J Mol Sci)
B-cell receptor (BCR) signaling was identified as the only enriched signal in DLBCL and pSS peripheral naive B-cells or salivary gland-infiltrated cells. The evaluation of the genes in association with BCR has revealed that targeting CD79A, CD79B, and LAMTOR4 as the shared genes can provide novel biomarkers for pSS progression into lymphoma.
Journal
|
CD79B (CD79b Molecule) • CD79A (CD79a Molecule) • LAMTOR4 (Late Endosomal/Lysosomal Adaptor)
over3years
AKT-mTORC1 reactivation is the dominant resistance driver for PI3Kβ/AKT inhibitors in PTEN-null breast cancer and can be overcome by combining with Mcl-1 inhibitors. (PubMed, Oncogene)
Parallel CRISPR screens in 3 PTEN-null breast cancer cell lines identified genes mediating resistance to capivasertib (AKT inhibitor) and AZD8186 (PI3Kβ inhibitor). The Mcl-1i + PI3Kβ/AKTi combination was effective across a panel of breast cancer cell lines with PIK3CA and PTEN mutations, and delivered increased anti-tumor benefit in vivo. This study demonstrates that different resistance drivers to PI3Kβi and AKTi converge to reactivate PI3K-AKT or mTOR signalling and combined inhibition of Mcl-1 and PI3K-AKT has potential as a treatment strategy for PI3Kβi/AKTi sensitive and resistant breast tumours.
Journal
|
HER-2 (Human epidermal growth factor receptor 2) • PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • PTEN (Phosphatase and tensin homolog) • ERBB3 (V-erb-b2 avian erythroblastic leukemia viral oncogene homolog 3) • TSC1 (TSC complex subunit 1) • PIK3CB (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit beta) • LAMTOR4 (Late Endosomal/Lysosomal Adaptor) • PIK3R2 (Phosphoinositide-3-Kinase Regulatory Subunit 2 )
|
PIK3CA mutation • PTEN mutation • TSC1 deletion • TSC1 deletion
|
Truqap (capivasertib) • AZD8186